{
    "Trade/Device Name(s)": [
        "Virtuoso\u2122M System for IHC PR (1E2)",
        "Virtuoso System for IHC PR (1E2)"
    ],
    "Submitter Information": "Ventana Digital Pathology",
    "510(k) Number": "K111869",
    "Predicate Device Reference 510(k) Number(s)": [
        "K073677"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NQN",
        "OEO"
    ],
    "Summary Letter Date": "January 17, 2012",
    "Summary Letter Received Date": "January 18, 2012",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 864.1860"
    ],
    "Regulation Name(s)": [
        "Immunohistochemistry reagents and kits"
    ],
    "Analyte Class(es)": [
        "anatomic pathology",
        "immunology"
    ],
    "Analyte(s)": [
        "Progesterone receptor (PR) protein"
    ],
    "Specimen Type(s)": [
        "Formalin-fixed, paraffin-embedded tissue"
    ],
    "Specimen Container(s)": [
        "Glass slide"
    ],
    "Instrument(s)/Platform(s)": [
        "iScan slide scanner",
        "Computer",
        "Virtuoso software"
    ],
    "Method(s)/Technology(ies)": [
        "Digital slide scanning",
        "Image analysis",
        "Immunohistochemistry (IHC)"
    ],
    "Methodologies": [
        "Semi-quantitative image analysis",
        "Digital read"
    ],
    "Submission Type(s)": [
        "System",
        "Software",
        "Accessory",
        "Analyzer"
    ],
    "Document Summary": "FDA 510(k) summary for Virtuoso System for IHC PR (1E2), a digital pathology and image analysis system for semi-quantitative assessment of PR protein in breast cancer tissue using immunohistochemical staining",
    "Indications for Use Summary": "Intended for in vitro diagnostic use as an aid to the pathologist in detection and semi-quantitative measurement of progesterone receptor (PR) protein in formalin-fixed, paraffin-embedded breast cancer tissue specimens, as an accessory to CONFIRMTM anti-Progesterone Receptor (PR) (1E2) Rabbit Monoclonal Primary Antibody assay for assessment of patients being considered for endocrine therapy.",
    "fda_folder": "Hematology"
}